Khan Sana*, Khan Neelam, Giri Sanjay, Parmar Manju, Khan Pathan Javed, Gehlod Mansi

Amaltas Institute of Pharmacy, Amaltas University, Dewas, (M.P), India

*Corresponding Author: Khan Sana, Department of Pharmacy, Amaltas Institute of Pharmacy, Amaltas University, Dewas, (M.P), India.

Received: March 22, 2024 ; Published: March 27, 2024

Abstract

Increase in prevalence of Diabetes Mellitus is a major public health problem. It is a progressive disorder which commonly requires multiple pharmacotherapies for managing blood glucose. Use of incretin based therapy is a potential solution for management of Type 2 DM. Glucagon-like peptide (GLP-1) is an incretin hormone which enhances serum insulin after food intake and it participates in glucose homeostasis and feeding behavior. Owing to high cost of treatment and general toxicity in long term use of GLP-1 agonist, hence there is review for GLP-1 receptor natural agonist which may enhance GLP-1 production. Recently, GLP-1 secretagogues activity of medicinal plants has been reported an increase in GLP-1 secretion by phytochemicals may help in management of T2DM with lesser side effects and low cost compared to the GLP-1 agonists of synthetic origin. Natural products have proven historically to be a promising pool of structures for drug discovery and a significant research effort has recently been undertaken to explore the GLP-1 activating potential of a wide range of natural products originating from traditionally used medicinal plants or dietary sources and they are a rich source for the discovery of novel GLP-1 activators. In this review, collection of GLP-1 activators from plant product that shows interaction with both catalytic site as well as secondary binding site of GLP-1 receptor were investigated and list of natural GLP-1 agonist was prepared which can be included in our dietary source. Thus almost 60% prevention of diabetes occur which is better than cure by synthetic drugs.

Keywords: Diabetes Mellitus; Secretagogues; Natural GLP-1 Agonist; Dietary Source; Prevention of Diabetes

References

1. Colip JB. “Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts”. American Journal 63 (1923): 391.
2. American Diabetes Association (ADA). “Classification and diagnosis of diabetes: standards of medical care in diabetes”. Diabetes Care5 (2019): 13-28.
3. Manandhar B and Ahn JM. “Glucagon-like peptide-1 (GLP-1) Analogs: Recent Advances, new possibilities and therapeutic implications”. 58.3 (2015): 1020-1037.
4. Michael A., et al. “GLP-1 receptor agonists in the treatment of type 2 diabetes – state of the art”. Molecular Metabolism 46 (2021): 101102.
5. Singh R., et al. “GLP-1 secretagogues potential of medicinal plants in management of diabetes”. Journal of Pharmacognosy and Phytochemistry1 (2021): 197-202.
6. Barrea L., et al. “Could hop- derived bitter compounds improve glucose homeostasis by stimulating the secretion of GLP-1”. Critical Reviews in Food Science and Nutrition3 (2021): 528-535.
7. Rios JL., et al. “Modulation of diabetes by natural products and medicinal plants via incertins”. 85 (2019): 825-839.
8. Kim KS., et al. “Medicinal plants Qua Glucagon-Like peptide -1 Secretagogue via Intestinal Nutrient Sensors”. 25 (2015): 9.
9. Shin MH., et al. “Hexane Fractions of Bupleurum falcatum L. Stimulates Glucagon-Like Peptide-1 Secretion through G-Mediated pathway”. 13 (2014).
10. Medagama AB. “The glycemic outcomes of cinnamon, a review of the experimental evidence and clinical trials”. Nutritional Journal 14 (2015): 108.
11. Zhang W., et al. “The emerging possibility of the use of geniposide in the treatment of cerebral diseases: A review”. Chinese Medicine 28 (2021): 16-86.
12. Chang CLT., et al. “Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology and potential Applications of Selected Plants and compounds”. Hindawi publishing (2013): 33.
13. Hussein GME., et al. “Mate tea (Ilex paraguariensis) promotes satiety and body weight lowering in mice: involvement of glucagon-like peptide-1”. Biological and Pharmaceutical Bulletin12 (2011): 1849-1855.
14. Li Ying., et al. “Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist”. FASEB6 (2019): 2603-2611.
15. Ucellatore A., et al. “Composition Review of short acting and Low acting Glucagon- like peptide-1 Receptor agonists”. Diabetes Therapy3 (2015): 39-56.
16. Choi EK., et al. “Hexane fraction of citrus aurantium L. stimulates glucagon-like peptide-1 (GLP-1) secretion via membrane depolarization in NCI-H716 cells”. BioChip Journal6 (2012): 41-47.
17. Hinnen D., et al. “Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes”. 30.3 (2017): 202-210.
18. Nauck AM., et al. “GLP-1 receptor agonist in the treatment of type 2 diabetes”. State of Aet Article 46 (2021): 101102.

Citation

Citation: Khan Sana., et al. “Glucagon Like Peptide 1 (GLP -1) Receptor Natural Agonist for the Treatment of Type 2 Diabetes Mellitus: A Review".Acta Scientific Pharmaceutical Sciences 8.5 (2024): 77-83.

Copyright

Copyright: © 2024 Khan Sana., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.